Envestnet Asset Management Inc. Purchases 102,375 Shares of Perrigo Company plc (NYSE:PRGO)

Envestnet Asset Management Inc. raised its position in shares of Perrigo Company plc (NYSE:PRGO - Free Report) by 26.8% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 484,805 shares of the company's stock after acquiring an additional 102,375 shares during the period. Envestnet Asset Management Inc. owned approximately 0.36% of Perrigo worth $13,594,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Headlands Technologies LLC raised its position in shares of Perrigo by 1,942.0% in the fourth quarter. Headlands Technologies LLC now owns 1,409 shares of the company's stock valued at $36,000 after buying an additional 1,340 shares in the last quarter. Parallel Advisors LLC raised its position in shares of Perrigo by 176.9% in the first quarter. Parallel Advisors LLC now owns 1,714 shares of the company's stock valued at $48,000 after buying an additional 1,095 shares in the last quarter. First Horizon Advisors Inc. raised its position in shares of Perrigo by 138.3% in the first quarter. First Horizon Advisors Inc. now owns 1,754 shares of the company's stock valued at $49,000 after buying an additional 1,018 shares in the last quarter. Fifth Third Bancorp raised its position in shares of Perrigo by 62.0% in the first quarter. Fifth Third Bancorp now owns 2,218 shares of the company's stock valued at $62,000 after buying an additional 849 shares in the last quarter. Finally, Blue Trust Inc. raised its position in shares of Perrigo by 110.4% in the first quarter. Blue Trust Inc. now owns 2,619 shares of the company's stock valued at $73,000 after buying an additional 1,374 shares in the last quarter. Institutional investors own 95.91% of the company's stock.

Perrigo Trading Down 0.7%

Perrigo stock traded down $0.20 during trading hours on Friday, reaching $26.95. 614,445 shares of the company's stock were exchanged, compared to its average volume of 1,424,250. The company has a quick ratio of 1.28, a current ratio of 2.36 and a debt-to-equity ratio of 0.82. The firm's 50 day simple moving average is $26.82 and its 200 day simple moving average is $26.13. Perrigo Company plc has a twelve month low of $23.14 and a twelve month high of $30.93. The firm has a market capitalization of $3.71 billion, a PE ratio of -20.57 and a beta of 0.45.

Perrigo (NYSE:PRGO - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.60 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.56 by $0.04. The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.09 billion. Perrigo had a negative net margin of 4.16% and a positive return on equity of 8.93%. The business's revenue was down 3.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.29 EPS. Research analysts predict that Perrigo Company plc will post 2.56 earnings per share for the current year.

Perrigo Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 17th. Investors of record on Friday, May 30th were given a $0.29 dividend. The ex-dividend date was Friday, May 30th. This represents a $1.16 annualized dividend and a yield of 4.30%. Perrigo's payout ratio is -88.55%.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded Perrigo from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $33.00.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.